ReviewAnnals of medicine2021
The cardiovascular aspect of COVID-19.
Review in Annals of medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Multifunctional ACE2-nanobody fusion design for pan-specific neutralization and cardiovascular protection in SARS coronavirus infection.Antimicrobial agents and chemotherapy · 2026Article
- Trend in Hospital Admissions for Cardiovascular Diseases (CVDs) Before and During the Coronavirus Disease 2019 (COVID-19) Pandemic: A Retrospective Analysis From a Sub-Urban Area in Sub-Saharan Africa.Health science reports · 2026Article
- Trends of cause-specific cardiovascular disease mortality in China, 2009-2019: a nationwide longitudinal study.Annals of medicine · 2025Article
- Translating animal models of SARS-CoV-2 infection to vascular, neurological and gastrointestinal manifestations of COVID-19.Disease models & mechanisms · 2025Review
- Consensus based recommendations for the management of post-COVID long-term sequelae (Long COVID): a regional perspective.Frontiers in medicine · 2025Article
- Cardiovascular Comorbidities in COVID-19: Comprehensive Analysis of Key Topics.Interactive journal of medical research · 2024Article
- Pathogenic mechanisms of cardiovascular damage in COVID-19.Molecular medicine (Cambridge, Mass.) · 2024Review
- Subclinical Myocardial Injury in Patients Recovered from COVID-19 Pneumonia: Predictors and Longitudinal Assessment.Journal of cardiovascular development and disease · 2023Article
- Strategies for the Emergency Treatment of Pregnant Women with Neurological Symptoms during the COVID-19 Pandemic.Aging and disease · 2023Article
- Heart Transplantation from COVID-19-Positive Donors: A Word of Caution.Transplantation proceedings · 2023Article
- Characterization of the angiotensin-converting enzyme 2 (ACE2), the main receptor for the SARS-CoV-2 virus.American journal of clinical and experimental immunology · 2023Review
- Effect of convalescent plasma therapy on mortality in moderate-to-severely Ill COVID-19 patients.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2022Article
- The RAAS Axis and SARS-CoV-2: From Oral to Systemic Manifestations.Medicina (Kaunas, Lithuania) · 2022Review
- Evidence mapping and review of long-COVID and its underlying pathophysiological mechanism.Infection · 2022Review
- COVID-19 and the cardiovascular system-current knowledge and future perspectives.World journal of clinical cases · 2022Review
- Capturing the value of vaccination: impact of vaccine-preventable disease on hospitalization.Aging clinical and experimental research · 2022Article
- COVID-19, Vaccines, and Thrombotic Events: A Narrative Review.Journal of clinical medicine · 2022Review
- Cardiovascular Risk Factors and Clinical Outcomes among Patients Hospitalized with COVID-19: Findings from the World Heart Federation COVID-19 Study.Global heart · 2022Article
- Post acute CoViD-19 syndrome (PACS) - Long CoViD.Bioinformation · 2022Article
- Early carbohydrate antigen 125 as a mortality predictor in hospitalized patients with coronavirus disease 2019.Frontiers in cardiovascular medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The coronavirus disease-2019 (COVID-19), an infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV-2), has hit the world very hard by affecting millions of people across countries hence posing a major health threat on a global scale. This novel virus is thought to enter and cause infection in its host through the attachment of its structural protein known as the S-glycoprotein to angiotensin-converting enzyme 2 (ACE2). Given the rapid spread of COVID-19 with its consequences globally, it is mandatory that health caregivers and researchers across all disciplines abreast themselves with the potential effects that this novel virus may have on their fields and the medical society at large. During the infection, the cardiovascular system is affected by unknown pathomechanistic processes, hence accounting for an increased prevalence of cardiovascular diseases (CVDs) among COVID-19 patients. As cardiovascular researchers, we are more concerned about the cardiovascular aspect of SARS-CoV-2/COVID-19. Hence, this concise review addresses these aspects where CVD as a risk factor of COVID-19, the prevalence of CVDs in COVID-19, and the potential cardiovascular disorders which may evolve owing to COVID-19 are discussed. A better understanding of these issues will be pivotal to improve cardiovascular health during this SARS-CoV-2/COVID-19 pandemic and beyond.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.